These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

360 related articles for article (PubMed ID: 17545710)

  • 1. The cost effectiveness of antiretroviral treatment strategies in resource-limited settings.
    Bishai D; Colchero A; Durack DT
    AIDS; 2007 Jun; 21(10):1333-40. PubMed ID: 17545710
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Resistance profiles after different periods of exposure to a first-line antiretroviral regimen in a Cameroonian cohort of HIV type-1-infected patients.
    Soria A; Porten K; Fampou-Toundji JC; Galli L; Mougnutou R; Buard V; Kfutwah A; Vessière A; Rousset D; Teck R; Calmy A; Ciaffi L; Lazzarin A; Gianotti N
    Antivir Ther; 2009; 14(3):339-47. PubMed ID: 19474468
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Monitoring of HIV viral load, CD4 cell count, and clinical assessment versus clinical monitoring alone for antiretroviral therapy in low-resource settings (Stratall ANRS 12110/ESTHER): a cost-effectiveness analysis.
    Boyer S; March L; Kouanfack C; Laborde-Balen G; Marino P; Aghokeng AF; Mpoudi-Ngole E; Koulla-Shiro S; Delaporte E; Carrieri MP; Spire B; Laurent C; Moatti JP;
    Lancet Infect Dis; 2013 Jul; 13(7):577-86. PubMed ID: 23602084
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Secure antiretroviral therapy delivery in a resource-limited setting: streamlined to minimize drug resistance and expense.
    Kitkungvan D; Apisarnthanarak A; Laowansiri P; Mundy LM
    HIV Med; 2008 Oct; 9(8):636-41. PubMed ID: 18643857
    [TBL] [Abstract][Full Text] [Related]  

  • 5. When to initiate highly active antiretroviral therapy in sub-Saharan Africa? A South African cost-effectiveness study.
    Badri M; Cleary S; Maartens G; Pitt J; Bekker LG; Orrell C; Wood R
    Antivir Ther; 2006; 11(1):63-72. PubMed ID: 16518961
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessing efficiency and costs of scaling up HIV treatment.
    Cleary SM; McIntyre D; Boulle AM
    AIDS; 2008 Jul; 22 Suppl 1():S35-42. PubMed ID: 18664951
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Conservation of first-line antiretroviral treatment regimen where therapeutic options are limited.
    Orrell C; Harling G; Lawn SD; Kaplan R; McNally M; Bekker LG; Wood R
    Antivir Ther; 2007; 12(1):83-8. PubMed ID: 17503751
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Challenges in implementing HIV laboratory monitoring in resource-constrained settings: how to do more with less.
    Bélec L; Bonn JP
    Future Microbiol; 2011 Nov; 6(11):1251-60. PubMed ID: 22082287
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of antiretroviral therapy programs in resource-poor settings: a meta-analysis of the published literature.
    Ivers LC; Kendrick D; Doucette K
    Clin Infect Dis; 2005 Jul; 41(2):217-24. PubMed ID: 15983918
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In resource-limited settings good early outcomes can be achieved in children using adult fixed-dose combination antiretroviral therapy.
    O'Brien DP; Sauvageot D; Zachariah R; Humblet P;
    AIDS; 2006 Oct; 20(15):1955-60. PubMed ID: 16988517
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness of screening for HIV in the era of highly active antiretroviral therapy.
    Sanders GD; Bayoumi AM; Sundaram V; Bilir SP; Neukermans CP; Rydzak CE; Douglass LR; Lazzeroni LC; Holodniy M; Owens DK
    N Engl J Med; 2005 Feb; 352(6):570-85. PubMed ID: 15703422
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The World Health Organization's global strategy for prevention and assessment of HIV drug resistance.
    Bennett DE; Bertagnolio S; Sutherland D; Gilks CF
    Antivir Ther; 2008; 13 Suppl 2():1-13. PubMed ID: 18578063
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness of laboratory monitoring for management of HIV treatment in sub-Saharan Africa: a model-based analysis.
    Hamers RL; Sawyer AW; Tuohy M; Stevens WS; Rinke de Wit TF; Hill AM;
    AIDS; 2012 Aug; 26(13):1663-72. PubMed ID: 22695297
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Economic evaluation of monitoring virologic responses to antiretroviral therapy in HIV-infected children in resource-limited settings.
    Schneider K; Puthanakit T; Kerr S; Law MG; Cooper DA; Donovan B; Phanuphak N; Sirisanthana V; Ananworanich J; Ohata J; Wilson DP
    AIDS; 2011 Jun; 25(9):1143-51. PubMed ID: 21505319
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Recommendations from the GESIDA/Spanish AIDS Plan regarding antiretroviral treatment in adults with human immunodeficiency virus infection (update February 2009)].
    Panel de expertos de Gesida y Plan Nacional sobre el Sida
    Enferm Infecc Microbiol Clin; 2009 Apr; 27(4):222-35. PubMed ID: 19246124
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Two-months-off, four-months-on antiretroviral regimen increases the risk of resistance, compared with continuous therapy: a randomized trial involving West African adults.
    Danel C; Moh R; Chaix ML; Gabillard D; Gnokoro J; Diby CJ; Toni T; Dohoun L; Rouzioux C; Bissagnene E; Salamon R; Anglaret X;
    J Infect Dis; 2009 Jan; 199(1):66-76. PubMed ID: 18986246
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CD8/CD38 activation yields important clinical information of effective antiretroviral therapy: findings from the first year of the CIPRA-SA cohort.
    Glencross DK; Janossy G; Coetzee LM; Lawrie D; Scott LE; Sanne I; McIntyre JA; Stevens W
    Cytometry B Clin Cytom; 2008; 74 Suppl 1():S131-40. PubMed ID: 18228566
    [TBL] [Abstract][Full Text] [Related]  

  • 18. National adult antiretroviral therapy guidelines in resource-limited countries: concordance with 2003 WHO guidelines?
    Beck EJ; Vitoria M; Mandalia S; Crowley S; Gilks CF; Souteyrand Y
    AIDS; 2006 Jul; 20(11):1497-502. PubMed ID: 16847404
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HIV-1 subtype E progression among northern Thai couples: traditional and non-traditional predictors of survival.
    Costello C; Nelson KE; Suriyanon V; Sennun S; Tovanabutra S; Heilig CM; Shiboski S; Jamieson DJ; Robison V; Rungruenthanakit K; Duerr A
    Int J Epidemiol; 2005 Jun; 34(3):577-84. PubMed ID: 15737969
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effectiveness and cost effectiveness of early and late prevention of HIV/AIDS progression with antiretrovirals or antibiotics in Southern African adults.
    Bachmann MO
    AIDS Care; 2006 Feb; 18(2):109-20. PubMed ID: 16338768
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.